NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $52 | -70.8% | 73,886 | -6.0% | 0.00% | -100.0% |
| Q4 2022 | $178 | -99.9% | 78,586 | -5.5% | 0.00% | -33.3% |
| Q3 2022 | $266,000 | -12.8% | 83,139 | +3.6% | 0.00% | 0.0% |
| Q2 2022 | $305,000 | -33.0% | 80,230 | -5.0% | 0.00% | -25.0% |
| Q1 2022 | $455,000 | -71.6% | 84,491 | -28.7% | 0.00% | -33.3% |
| Q4 2021 | $1,600,000 | -31.3% | 118,484 | -8.6% | 0.01% | -70.0% |
| Q3 2021 | $2,329,000 | -4.8% | 129,667 | -9.0% | 0.02% | 0.0% |
| Q2 2021 | $2,446,000 | +463.6% | 142,543 | +557.1% | 0.02% | +25.0% |
| Q1 2021 | $434,000 | +10.4% | 21,693 | -6.1% | 0.02% | +6.7% |
| Q4 2020 | $393,000 | +2.9% | 23,113 | +0.4% | 0.02% | -11.8% |
| Q3 2020 | $382,000 | -28.7% | 23,032 | -0.5% | 0.02% | -32.0% |
| Q2 2020 | $536,000 | -22.9% | 23,143 | -40.6% | 0.02% | +47.1% |
| Q1 2020 | $695,000 | -18.7% | 38,952 | -1.7% | 0.02% | +6.2% |
| Q4 2019 | $855,000 | +27.0% | 39,608 | +7.1% | 0.02% | +14.3% |
| Q3 2019 | $673,000 | -48.2% | 36,966 | +1.4% | 0.01% | -53.3% |
| Q2 2019 | $1,298,000 | +64.3% | 36,469 | +55.2% | 0.03% | +57.9% |
| Q1 2019 | $790,000 | +4.4% | 23,498 | +2.0% | 0.02% | -9.5% |
| Q4 2018 | $757,000 | -47.5% | 23,036 | -2.7% | 0.02% | -41.7% |
| Q3 2018 | $1,443,000 | +21.0% | 23,677 | -3.1% | 0.04% | +24.1% |
| Q2 2018 | $1,193,000 | -50.3% | 24,427 | +8.0% | 0.03% | -54.7% |
| Q1 2018 | $2,402,000 | +84.8% | 22,609 | +3.8% | 0.06% | +82.9% |
| Q4 2017 | $1,300,000 | +164.8% | 21,775 | +6.3% | 0.04% | +133.3% |
| Q3 2017 | $491,000 | +22.1% | 20,477 | -0.4% | 0.02% | +15.4% |
| Q2 2017 | $402,000 | -9.5% | 20,563 | +8.7% | 0.01% | -40.9% |
| Q1 2017 | $444,000 | +91.4% | 18,919 | -0.1% | 0.02% | +120.0% |
| Q4 2016 | $232,000 | -10.1% | 18,939 | +26.1% | 0.01% | -33.3% |
| Q3 2016 | $258,000 | 0.0% | 15,019 | -0.0% | 0.02% | 0.0% |
| Q2 2016 | $258,000 | +35.8% | 15,020 | +8.5% | 0.02% | -21.1% |
| Q1 2016 | $190,000 | -10.8% | 13,843 | +9.8% | 0.02% | -26.9% |
| Q4 2015 | $213,000 | +40.1% | 12,612 | -8.9% | 0.03% | +62.5% |
| Q3 2015 | $152,000 | -10.6% | 13,842 | +1.7% | 0.02% | -5.9% |
| Q2 2015 | $170,000 | – | 13,608 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |